Jpmorgan Chase & CO Praxis Precision Medicines, Inc. Transaction History

Jpmorgan Chase & CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.83 - $1.18 $30,324 - $43,112	-36,536 Reduced 96.14%	1,465 $1,000
Q1 2023 May 18, 2023	BUY	$0.8 - $4.98 $29,228 - $181,949	36,536 Added 2493.92%	38,001 $30,000
Q1 2023 May 11, 2023	SELL	$0.8 - $4.98 $17,132 - $106,646	-21,415 Reduced 93.6%	1,465 $1,000
Q4 2022 Feb 13, 2023	SELL	$1.88 - $2.49 $1,423 - $1,884	-757 Reduced 3.2%	22,880 $54,000
Q3 2022 Nov 14, 2022	BUY	$2.5 - $4.77 $2,890 - $5,514	1,156 Added 5.14%	23,637 $53,000

Q2 2022 Aug 11, 2022	SELL	$1.75 - $11.34 $19,799 - $128,300	-11,314 Reduced 33.48%	22,481 $55,000
Q1 2022 May 11, 2022	BUY	$10.21 - $20.29 $51,274 - $101,896	5,022 Added 17.45%	33,795 $345,000
Q4 2021 Feb 10, 2022	BUY	$16.76 - $22.99 $96,319 - $132,123	5,747 Added 24.96%	28,773 $568,000
Q3 2021 Nov 12, 2021	BUY	$13.15 - $22.56 $302,791 - $519,466	23,026 New	23,026 $425,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $1.84B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.